{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:09:15Z","timestamp":1772770155209,"version":"3.50.1"},"reference-count":101,"publisher":"Informa UK Limited","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2002,7]]},"DOI":"10.1517\/13543784.11.7.911","type":"journal-article","created":{"date-parts":[[2005,5,4]],"date-time":"2005-05-04T16:35:33Z","timestamp":1115224533000},"page":"911-925","source":"Crossref","is-referenced-by-count":11,"title":["Antibiotics in the treatment of acute exacerbations of chronic bronchitis"],"prefix":"10.1517","volume":"11","author":[{"given":"Lisa L","family":"Dever","sequence":"first","affiliation":[{"name":"VA New Jersey Health Care System, East Orange, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"WG","family":"Johanson","sequence":"additional","affiliation":[{"name":"VA New Jersey Health Care System, East Orange, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavitha","family":"Shashikumar","sequence":"additional","affiliation":[{"name":"VA New Jersey Health Care System, East Orange, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2005,2,24]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"380","article-title":"Risk of chronic obstructive pulmonary disease","volume":"130","author":"HIGGINS MW","year":"1984","unstructured":"HIGGINS MW, KELLER JB, LANDIS JR et al.: Risk of chronic obstructive pulmonary disease. Collaborative assessment of the validity of the Tecumseh index of risk. Am. Rev Respir. Dis. (1984) 130:380\u2013385.","journal-title":"Collaborative assessment of the validity of the Tecumseh index of risk. Am. Rev Respir. Dis."},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5288.740"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)07493-4"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-106-2-196"},{"key":"e_1_2_1_6_1","unstructured":"\u2022\u2022A now classic study that stratified patientswith AECB into three levels based on severity of symptoms and found a significant benefit of antibiotic therapy in patients with more severe disease."},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/003591575604901009"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(59)90099-6"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.6.1542"},{"key":"e_1_2_1_10_1","unstructured":"\u2022The authors found a correlation between deterioration of lung function and the types of bacteria isolated. Patients with more severe disease (FEV1 35% of predicted) were more likely to have Gram-negative bacilli."},{"key":"e_1_2_1_11_1","first-page":"907","article-title":"The course of chronic hemophilus bronchitis treated with massive doses of penicillin and penicillin combined with streptomycin","volume":"101","author":"JENNE JW","year":"1970","unstructured":"JENNE JW, MACDONALD FM, LAPINSKI EM, BRATBERG NE, HALL WH: The course of chronic hemophilus bronchitis treated with massive doses of penicillin and penicillin combined with streptomycin. Am. Rev. Respir. Dis. (1970) 101:907\u2013922.","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_2_1_12_1","unstructured":"\u2022Patients treated with penicillin and streptomycin treatment had eradication of H inthrenzae from sputum and prolonged remissions."},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.11.2104093"},{"key":"e_1_2_1_14_1","first-page":"1004","article-title":"Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis","volume":"142","author":"FAGON JY","year":"1990","unstructured":"FAGON JY, CHASTRE J, TROUILLET JL et al: Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am. Rev Respir. Dis. (1990) 142:1004\u20131008.","journal-title":"Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am. Rev Respir. Dis."},{"key":"e_1_2_1_15_1","unstructured":"\u2022Carefully done study that found 50% of patients had sterile distal bronchial cultures during episodes of AECB."},{"key":"e_1_2_1_16_1","first-page":"1316","article-title":"Bacterial infection in chronic obstructive pulmonary disease","volume":"152","author":"MONSO E","year":"1995","unstructured":"MONSO E, RUIZ J, ROSELL A et al: Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am. Respir. Crit. Care Med. (1995) 152:1316\u20131320.","journal-title":"A study of stable and exacerbated outpatients using the protected specimen brush. Am. Respir. Crit. Care Med."},{"key":"e_1_2_1_17_1","unstructured":"\u2022The investigators demonstrated that distal airways of COPD patients often contain bacteria during quiescent periods but episodes of AECB were associated with more widespread colonisation and higher bacterial densities."},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.152.1.7599829"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1086\/514119"},{"key":"e_1_2_1_20_1","doi-asserted-by":"crossref","unstructured":"SETHI S: Infectious etiology of acute exacerbations of chronic bronchitis. Chest (2000) 117:380S\u2013385S.","DOI":"10.1378\/chest.117.5_suppl_2.380S"},{"key":"e_1_2_1_21_1","unstructured":"\u2022Review of the infectious aetiologies of AECB by an expert in the field."},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI103791"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.4.1422"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.2000.16d19.x"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/137.4.377"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.1.9809041"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.15.1.125-144.2002"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5056.1272"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(60)90056-8"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0007-0971(62)80012-6"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5467.904"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1967.tb11527.x"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5607.735"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0007-0971(72)90016-2"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-97-1-18"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.3109\/02813439209014027"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.50.7.758"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)07097-0"},{"key":"e_1_2_1_39_1","unstructured":"\u2022Patients that received ofloxacin had shorter hospital stays lower mortality and required fewer courses of other antibiotics."},{"key":"e_1_2_1_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03520360071042"},{"key":"e_1_2_1_41_1","unstructured":"\u2022\u2022Meta-analysis of nine placebo-controlledstudies found a small but statistically significant benefit of antibiotics."},{"key":"e_1_2_1_42_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.5.1345"},{"key":"e_1_2_1_43_1","unstructured":"\u2022Patients treated with antibiotics other than arnoxicillin had lower relapse rates. Those treated with arnoxicillin had higher rates of relapse than those that received no antibiotics."},{"key":"e_1_2_1_44_1","doi-asserted-by":"crossref","unstructured":"DESTACHE CJ DEWAN N O'DONOHUE WJ CAMPBELL JC ANGELILLO VA: Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J. Antimicrob. Chemother. (1999) 43(Suppl. A):107\u2013113.","DOI":"10.1093\/jac\/43.suppl_1.107"},{"key":"e_1_2_1_45_1","unstructured":"\u2022Retrospective study showing treatment failures were more likely with first-line' antibiotics (arnoxicillin erythromycin tetracycline and co-trirnoxazole). Overall treatment costs were lower with 'third-line' antibiotics (arnoxicillin-davulanate azithromycin and ciprofloxacin)."},{"key":"e_1_2_1_46_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.117.3.662"},{"key":"e_1_2_1_47_1","unstructured":"\u2022Patient host factors including FEV1 35% but not choice of antibiotic were associated with treatment failures."},{"key":"e_1_2_1_48_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.6.1721-1729.2001"},{"key":"e_1_2_1_49_1","doi-asserted-by":"crossref","unstructured":"THORNSBERRY C SAHM DF: Resistancein respiratory tract pathogens: an international study 1997\u20131998.1 Chemother. (2000) 12\\(Suppl. 4):16\u201320.","DOI":"10.1080\/1120009X.2000.11782308"},{"key":"e_1_2_1_50_1","unstructured":"\u2022In vitro study of over 11 000 respiratory isolates from 9 countries showing marked variability in susceptibility to antibiotics commonly used to treat respiratory infections."},{"key":"e_1_2_1_51_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-9863"},{"key":"e_1_2_1_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.21.2538"},{"key":"e_1_2_1_53_1","unstructured":"NATIONAL COMMITTEE FOR CLINCAL AND LABORATORY STANDARDS: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standards. 5th edn. (2000). National Committee for Clinical and Laboratory Standards. Wayne PA USA."},{"key":"e_1_2_1_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012122"},{"key":"e_1_2_1_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)87973-4"},{"key":"e_1_2_1_56_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.5.417.35062"},{"key":"e_1_2_1_57_1","doi-asserted-by":"crossref","unstructured":"FORREST A CHODOSH S AMANTEA MA COLLINS DA SCHENTAG JJ: Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. Antimicrob. Chemother: (1997) 40(Suppl. A):45\u201357.","DOI":"10.1093\/jac\/40.suppl_1.45"},{"key":"e_1_2_1_58_1","doi-asserted-by":"crossref","unstructured":"LEVISON ME: Pharmacodynamics of antibacterial drugs. Infect. Dis. Clin. North Am. (2000) 14:281-91 vii.","DOI":"10.1016\/S0891-5520(05)70248-8"},{"key":"e_1_2_1_59_1","doi-asserted-by":"crossref","unstructured":"EBERT SC: Pharmacokinetic and pharmacodynamic considerations in antibiotic selection for different pneumonia settings. Infect. Dis. Clin. Frac. (1997) 6(2 Suppl.):S43\u2013S48.","DOI":"10.1097\/00019048-199711002-00004"},{"key":"e_1_2_1_60_1","unstructured":"\u2022Contains a table detailing the penetration of antibiotics into the respiratory tract."},{"key":"e_1_2_1_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.6.1399"},{"key":"e_1_2_1_62_1","doi-asserted-by":"publisher","DOI":"10.1053\/rmed.2000.0927"},{"key":"e_1_2_1_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(98)00008-9"},{"key":"e_1_2_1_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80033-3"},{"key":"e_1_2_1_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00435-6"},{"key":"e_1_2_1_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01728910"},{"key":"e_1_2_1_67_1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1742-1241.1998.tb11633.x","article-title":"Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis","volume":"52","author":"LANGAN C","year":"1998","unstructured":"LANGAN C, CLECNER B, CAZZOLA CM et al: Short-course cefuroxime axetil therapy in the treatment of acute exacerbations of chronic bronchitis. Int. J. Clin. Pract. (1998) 52:289\u2013297.","journal-title":"Int. J. Clin. Pract."},{"key":"e_1_2_1_68_1","unstructured":"RUSSO RL D'APRILE M: Role of antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease."},{"key":"e_1_2_1_69_1","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Ann. Pharmacother. (2001) 35:576\u2013581.","DOI":"10.1345\/aph.19411"},{"key":"e_1_2_1_70_1","doi-asserted-by":"crossref","unstructured":"HOEPELMAN IM MOLLERS MJ VAN SCHIE MH et al.: A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Irk. I Antimicrob. Agents (1997) 9:141\u2013146.","DOI":"10.1016\/S0924-8579(97)00043-5"},{"key":"e_1_2_1_71_1","doi-asserted-by":"publisher","DOI":"10.1177\/147323000002800301"},{"key":"e_1_2_1_72_1","doi-asserted-by":"crossref","unstructured":"DUNN CJ BARRADELL LB: Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs (1996) 51:483\u2013505.","DOI":"10.2165\/00003495-199651030-00013"},{"key":"e_1_2_1_73_1","doi-asserted-by":"crossref","unstructured":"CHODOSH S: Use of quinolones for thetreatment of acute exacerbations of chronic bronchitis. Am. I Med. (12-30-1991) 91:93S\u2013100S.","DOI":"10.1016\/0002-9343(91)90318-R"},{"key":"e_1_2_1_74_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.1.131"},{"key":"e_1_2_1_75_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.4.529"},{"key":"e_1_2_1_76_1","doi-asserted-by":"crossref","unstructured":"RADEMAKER CM SIPS AP BEUMER HM et al.: A double-blind comparison of low-dose ofloxacin and amoxycillin\/ clavulanic acid in acute exacerbations of chronic bronchitis. I. Antimicrob. Chemother: (1990) 26(Suppl. D):75\u201381.","DOI":"10.1093\/jac\/26.suppl_D.75"},{"key":"e_1_2_1_77_1","first-page":"41","article-title":"Oral ofloxacin once daily and doxycycline in the treatment of acute exacerbations of chronic bronchitis","volume":"68","author":"PUNAKIVI L","year":"1990","unstructured":"PUNAKIVI L, KEISTINEN T, BACKMAN R et al: Oral ofloxacin once daily and doxycycline in the treatment of acute exacerbations of chronic bronchitis. Scand. .1 Infect. Dis. Sapp]. (1990) 68:41\u201345.","journal-title":"Scand. .1 Infect. Dis. Sapp]."},{"key":"e_1_2_1_78_1","doi-asserted-by":"crossref","unstructured":"DAVIES BI MAESEN FP: Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity. Antimicrob. Chemother: (1999) 43(Suppl. C):83\u201390.","DOI":"10.1093\/jac\/43.suppl_3.83"},{"key":"e_1_2_1_79_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.2.199"},{"key":"e_1_2_1_80_1","doi-asserted-by":"publisher","DOI":"10.1177\/147323000102900408"},{"key":"e_1_2_1_81_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.2.353"},{"key":"e_1_2_1_82_1","first-page":"1691","author":"JOHNSON AP","year":"2001","unstructured":"JOHNSON AP: Telithromycin. Aventis Pharma. Curr. Opin. Livestig. Drugs (2001) 2:1691\u20131701.","journal-title":"Aventis Pharma. Curr. Opin. Livestig. Drugs"},{"key":"e_1_2_1_83_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2000.00185.x"},{"key":"e_1_2_1_84_1","unstructured":"GIA H. ROEDER V NAMOUR F SULTAN E LEFANT B: Telithromycin (HMR 3647) achieves high and sustained concentrations in white blood cells in man. 5th International Conference on the Macrolides Azalides Streptogramins Ketolides and Oxazolidinones. (2000) Seville Spain."},{"key":"e_1_2_1_85_1","unstructured":"AUBIER M AKDIBSM 0.M. LEAK A et al: Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial telithromycin (HMR 3647) for the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with COPD. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (2000) Toronto Canada."},{"key":"e_1_2_1_86_1","unstructured":"DEABATE CA HEYDER A. LEROY B SIDAROUS E BACKSTORM J: Oral telithromycin (HMR 3647) 800 mg once daily for 5 days is well tolerated and as effective as cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (2000) Toronto Canada."},{"key":"e_1_2_1_87_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.10.2.343"},{"key":"e_1_2_1_88_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262010-00002"},{"key":"e_1_2_1_89_1","unstructured":"\u2022Thorough review of flouoroquinolones used in the treatment of respiratory infections."},{"key":"e_1_2_1_90_1","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2001.13.3.288"},{"key":"e_1_2_1_91_1","doi-asserted-by":"crossref","unstructured":"FILET SCHLEMMER B GARAU Jet al.: Gemifloxacin versus amoxicillin\/clavulanate in the treatment of acute exacerbations of chronic bronchitis. The 070 Clinical Study group. J. Chemother: (2000) 12:314\u2013325.","DOI":"10.1179\/joc.2000.12.4.314"},{"key":"e_1_2_1_92_1","doi-asserted-by":"crossref","unstructured":"MILATOVIC D SCHMITZ FJ BRISSE S VERHOEF J FLUIT AC: In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8 796 clinical bacterial isolates. Antimicrob. Agents Chemother: (2000) 44:1102\u20131107.","DOI":"10.1128\/AAC.44.4.1102-1107.2000"},{"key":"e_1_2_1_93_1","doi-asserted-by":"crossref","unstructured":"FUNG-TOMC JC MINASSIAN B KOLEK B et al.: Antibacterial spectrum of a novel des-fluoro(6) quinolone BMS-284756. Antimicrob. Agents Chemother: (2000) 44:3351\u20133356.","DOI":"10.1128\/AAC.44.12.3351-3356.2000"},{"key":"e_1_2_1_94_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.5.1463-1466.2001"},{"key":"e_1_2_1_95_1","unstructured":"FORGARTY C MILANOWSKI J HEYDER A et al.: A randomized double-blind multicenter study of 5 day and 10 day therapy with oral BMS-284756 in the treatment of acute exacerbation of chronic bronchitis (AECB). 41st Literscience Conference on Antimicrobial Agents and Chemotherapy (2001) Chicago IL USA."},{"key":"e_1_2_1_96_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.5499.1317"},{"key":"e_1_2_1_97_1","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.176.25"},{"key":"e_1_2_1_98_1","unstructured":"BALTER MS HYLAND RH LOW DE et al.: Recommendations on the management of chronic bronchitis: A practical guide for Canadian physicians. Can. Med. Assoc. (1994) 151 Suppl. 10:5\u201323."},{"key":"e_1_2_1_99_1","unstructured":"\u2022\u2022Expert panel proposed stratifying patients based on age number and severity of symptoms degree of airflow obstruction frequency of exacerbations and comorbid conditions."},{"key":"e_1_2_1_100_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-7-200104030-00016"},{"key":"e_1_2_1_101_1","doi-asserted-by":"crossref","unstructured":"GROSSMAN R: Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest (1997) 112:310S\u2013313S.","DOI":"10.1378\/chest.112.6_Supplement.310S"},{"key":"e_1_2_1_102_1","unstructured":"\u2022\u2022Proposed stratification of patients fortreatment by risk factors."}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543784.11.7.911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:55:18Z","timestamp":1772765718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543784.11.7.911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7]]},"references-count":101,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002,7]]}},"alternative-id":["10.1517\/13543784.11.7.911"],"URL":"https:\/\/doi.org\/10.1517\/13543784.11.7.911","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7]]}}}